RENB250516C1500
- 0.00
- 0.000.00%
Renovaro Newsroom
Renovaro Expands Ongoing Strategic Collaboration With Nebul To Advance Early Detection Of Cancer And Other Diseases
Renovaro Secures High-Powered Computing From Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs
Express News | Predictive Oncology Inc - Denies Entering Merger Agreement With Renovaro - SEC Filing
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press Release: Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine
Renovaro Shares Fall After Merger Setback
Renovaro Says Predictive Oncology Terminates Merger Deal; Shares Fall
Renovaro: 'POI Must Comply With the Binding Obligations' of Deal, Must 'Enter Into an Exclusive License Agreement' >RENB
Renovaro Biosciences Responds To Predictive Oncology's Termination Of Merger Agreement, Asserting Breach Of Binding Contracts And Intent To Pursue Legal Remedies For Damages And Non-Compliance With Exclusive License Agreement
Renovaro: POI 'Has Caused Substantial Damage to Renovaro for Which It Will Seek Redress' >RENB
Express News | Renovaro Inc - to Seek Legal Remedies if No License Agreement by April 10
Express News | Renovaro Inc - Claims Poi in Breach of Binding Agreements
Express News | Renovaro Inc - Predictive Oncology Terminates Merger Transaction With Renovaro
Renovaro (RENB) and Predictive Oncology Partner for AI-Driven Drug Discovery: What's Next for Cancer and HIV Treatments?
Express News | Renovaro Completes First Milestone Payment to Finalize Definitive Agreement With Predictive Oncology
Express News | Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Press Release: Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences
Sector Update: Health Care Stocks Decline Late Afternoon
Sector Update: Health Care
Renovaro Biosciences Buys AI-Driven BioSymetrics